- August 14, 2018
Lyme Disease Is Spreading Fast. Why Isn’t There a Vaccine?
The only vaccine was taken off the market more than 15 years ago. As reports of the disease skyrocket, researchers are working on a new one.
- August 6, 2018
Samumed raises $438 million for regenerative therapies
Samumed, LLC has raised $438 million, the San Diego regenerative medicine company said Monday. The new financing round brings the total to more than $650 million since Samumed’s founding, valuing the company at $12 billion, the privately held company said.
- August 6, 2018
Experimental Drug Keeps Father Of Two From Needing Kidney Transplant
“We’re studying a medicine called bardoxolone methyl. It’s made by a company called Reata,” explained Block. Hinerfeld was the first person with Alport Syndrome to try bardoxolone. Block said, after 12 weeks, Hinerfeld’s kidney function stopped declining and actually improved.
- August 2, 2018
Celtaxsys cystic fibrosis drug reduces key symptom in mid-stage study
Privately held Celtaxsys Inc said on Thursday a mid-stage trial testing its experimental cystic fibrosis treatment was successful in reducing a key symptom of the genetic lung disease, but did not improve lung function.
- August 2, 2018
Celtaxsys’ cystic fibrosis drug reduces lung exacerbations in phase 2 study
Celtaxsys’ oral anti-inflammatory drug for cystic fibrosis, acebilustat, cleared a phase 2 study by demonstrating meaningful improvements in pulmonary exacerbations, or the acute worsening of symptoms such as heavy coughing or shortness of breath, combined with sharp decreases in lung function following irreversible organ damage.
- July 24, 2018
First Human Trial to Evaluate QR-313 for Dystrophic Epidermolysis Bullosa Initiated
While there are currently no approved treatments for the rare skin disease, there are therapies in development, such as ProQR’s RNA therapy, QR-313, which is now being evaluated in its first human clinical trial, dubbed “WINGS.”
- July 23, 2018
This Biotech Stock Rocketed 40% On Kidney Disease Drug Study
Reata Pharmaceuticals (RETA) skyrocketed to a record high Monday after its experimental drug crushed expectations in two groups of chronic kidney disease patients. Reata said its drug known as bardoxolone methyl benefited patients with what’s known as Alport syndrome and autosomal dominant orphan kidney disease.
- July 13, 2018
Arrowhead Takes Flight
Shares of Pasadena’s Arrowhead Pharmaceuticals Inc. take flight.
